Osteosarcoma in Pediatric Patients and Young Adults: A Single Institution Retrospective Review of Presentation, Therapy, and Outcome
Figure 3
Localized disease outcomes for pediatric and YA cohorts demonstrate better overall survival in pediatric cohort and improved 3-year EFS for MAP+ YA patients. (a) Five-year overall survival of patients with localized disease in the pediatric and YA cohort (). (b) Three-year EFS for pediatric cohort and YA cohort (). (c) Three-year EFS of YA patients who received less chemotherapy than the typical pediatric regimen (MAP−) compared to YA patients who received the typical pediatric regimen (MAP+) (). (d) Three-year EFS of YA MAP− patients compared to YA MAP+ patients. Patients who had recurrence during primary MAP therapy were removed ().
